Overall, the novel regulatory mechanism of caspase-1/IL1B and CD44s, both in normoxia and hypoxia conditions, will deepen our understanding of HCC progression and provide new targets for pharmacotherapeutic intervention. The gene discussed is CASP1; the disease is hepatocellular carcinoma.